Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Metabolism

Background:

• Inhibition of oxidative phosphorylation (OXPHOS) alone is insufficient to eliminate human cancer cells.
• Identifying synergistic drug combinations is crucial for effective cancer therapy.

Purpose of the Study:

• To discover agents with synthetic lethal interactions with OXPHOS inhibitors.
• To investigate the combination of BAY87-2243 and dimethyl α-ketoglutarate (DMKG) for cancer treatment.

Main Methods:

• In vitro and in vivo studies using cancer cell lines and animal models.
• Analysis of transcriptional reprogramming, alternative exon usage, and metabolic pathways.
• Assessment of cell death pathways, including mitochondrial integrity and key protein activation.

Main Results:

• DMKG, a cell-permeable α-ketoglutarate precursor, synergizes with BAY87-2243 (a complex I inhibitor) to kill cancer cells.
• The combination therapy blocks both OXPHOS and glycolysis, inducing a bioenergetic catastrophe.
• This leads to MDM2-dependent, TP53-independent transcriptional reprogramming and activation of cell death pathways.

Conclusions:

• Simultaneous inhibition of OXPHOS and glycolysis represents a viable therapeutic strategy against cancer.
• This approach exploits a metabolic vulnerability in human cancer cells.
• The combination of DMKG and OXPHOS inhibitors may form the basis for new anti-cancer regimens.